iBio to Participate in the H.C. Wainwright Global Investment Conference
iBio, Inc. (NYSEA:IBIO) will participate in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
iBio, Inc. (NYSEA:IBIO) will participate in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The company is known for its innovative FastPharming® Manufacturing System for biopharmaceuticals. A pre-recorded presentation will be available on demand for registered attendees starting May 24, 2022, and can also be accessed on iBio's website under 'News & Events'. iBio focuses on developing biopharmaceuticals for cancer, fibrotic, and infectious diseases, leveraging its state-of-the-art manufacturing capabilities.
Details
News Market Reaction – IBIO
The recorded move for IBIO in the trading session of this news was -7.55%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRYAN, Texas, May 18, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming® Manufacturing System, today announced that it will participate virtually in the H.C. Wainwright Global Investment Conference. The hybrid conference will take place May 23-26, 2022.
iBio's pre-recorded presentation will be available on demand during the event for all registered attendees. Beginning on Tuesday, May 24, 2022, the presentation will also be available on the Company's website at www.ibioinc.com under "News & Events" in the Investors section.
About iBio, Inc.
iBio is a developer of next-generation biopharmaceuticals and a pioneer in sustainable, plant-based biologics manufacturing. Its FastPharming® System combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. iBio is developing proprietary biopharmaceuticals for the treatment of cancers, as well as fibrotic and infectious diseases. The Company’s wholly-owned subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with GlycaneeringSM Development Services for advanced recombinant protein design. For more information, visit www.ibioinc.com.
Contact:
Stephen Kilmer
iBio, Inc.
Investor Relations
(646) 274-3580
skilmer@ibioinc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.